|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | EGFR是晚期食管腺癌患者预后的独立预测因子显示文摘食管腺癌是西方国家中发病率增加最快的恶性肿瘤之一,患者的5年生存率低于20%。以铂类药物为基础的新辅助化疗是治疗晚期食管腺癌的标准方案,虽然新辅助化疗能够延长部分化疗有效病人的生存期,但是仍有许多患者死于肿瘤复发。EGFR(表皮生长因子受体)是肿瘤细胞增殖信号通路中重要的调节因子,参与调控细胞增殖,转移和组织再生。研究发现EGFR高表达和EGFR基因组扩增与直接接受手术治疗的晚期食管腺癌患者预后不良有关,然而,对于接受过新辅助化疗的患者,EGFR的表达水平与其预后的关系仍不清楚。为此,德国的Walch教授等开展了一项研究,旨在探讨接受过以铂类药物为基础的新辅助化疗的晚期食管腺癌患者中, | Aichler M Motschmann M Jutting U | 2014 | 中华结直肠疾病电子杂志2014，3，5： | 6 |
| 2 | Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria显示文摘 | Michaela Aichler Mareike Elsner Natalie Ludyga Annette Feuchtinger Verena Zangen Stefan K Maier Benjamin Balluff Cédrik Sch?ne Ludwig Hierber Herbert Braselmann Stephan Meding Sandra Rauser Hans Zischka Michaela Aubele Manfred Schmitt Marcus Feith Stefani | 2013 | J Pathol2013，，4： | 1 |
| 3 | Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria显示文摘 | Michaela Aichler Mareike Elsner Natalie Ludyga Annette Feuchtinger Verena Zangen Stefan K Maier Benjamin Balluff Cédrik Sch?ne Ludwig Hierber Herbert Braselmann Stephan Meding Sandra Rauser Hans Zischka Michaela Aubele Manfred Schmitt Marcus Feith Stefani | 2013 | J Pathol2013，，4： | 1 |
| 4 | T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice显示文摘 | Karin Krebs Nina B?ttinger Li–Rung Huang Markus Chmielewski Silke Arzberger Georg Gasteiger Clemens J?ger Edgar Schmitt Felix Bohne Michaela Aichler Wolfgang Uckert Hinrich Abken Mathias Heikenwalder Percy Knolle Ulrike Protzer | 2013 | Gastroenterology2013，，2： | 1 |
| 5 | Proteomic and metabolic prediction of response to therapy in gastric cancer显示文摘Several new treatment options for gastric cancer have been introduced but the prognosis of patients diagnosed with gastric cancer is still poor. Disease prognosis could be improved for high-risk individuals by implementing earlier screenings. Because many patients are asymptomatic during the early stages of gastric cancer,the diagnosis is often delayed and patients present with unresectable locally advanced or metastatic disease. Cytotoxic treatment has been shown to prolong survival in general,but not all patients are responders. The application of targeted therapies and multimodal treatment has improved prognosis for those with advanced disease.However,these new therapeutic strategies do not uniformly benefit all patients.Predicting whether patients will respond to specific therapies would be of particular value and would allow for stratifying patients for personalized treatment strategies.Metabolic imaging by positron emission tomography was the first technique with the potential to predict the response of esophagogastric cancer to neoadjuvant therapy.Exploring and validating tissue-based biomarkers are ongoing processes.In this review,we discuss the status of several targeted therapies for gastric cancer,as well as proteomic and metabolic methods for investigating biomarkers for therapy response prediction in gastric cancer. | Michaela Aichler Birgit Luber Florian Lordick Axel Walch | 2014 | World Journal of Gastroenterology2014，20，38： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员